Clinical Trials Logo

Carcinoma, Bronchogenic clinical trials

View clinical trials related to Carcinoma, Bronchogenic.

Filter by:

NCT ID: NCT04776447 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

APOLO
Start date: June 16, 2021
Phase: Phase 2
Study type: Interventional

Open-label, non-randomized, phase II multi-centre controlled clinical trial. 51 non-resectable stage IIIA-IIIB non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of the treatment (Atezolizumab + Induction chemotherapy (CT) + CT-Radiotherapy) in terms of the Progression Free Survival at 12 months

NCT ID: NCT04697446 Enrolling by invitation - Neoplasms Clinical Trials

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Start date: December 1, 2020
Phase:
Study type: Observational

This is an external control, observational, retrospective study designed to compare clinical outcomes for pralsetinib compared with best available therapy for patients with RET-fusion positive advanced NSCLC.

NCT ID: NCT04667065 Completed - Lung Cancer Clinical Trials

Evaluation of a Remotely Guided Physical Preparation by a Physical Activity Teacher Adapted With the Help of a Smartwatch Before Bronchial Cancer Surgery

PREPACHIR
Start date: March 1, 2021
Phase: N/A
Study type: Interventional

This is a study of a preoperative rehabilitation program with remotely guided high-intensity exercises by physical activity teachers adapted to a smartwatch in patients with operable lung cancer.

NCT ID: NCT04644315 Terminated - Melanoma Clinical Trials

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

ALpha-T
Start date: May 24, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.

NCT ID: NCT04517019 Recruiting - Clinical trials for Head and Neck Cancer

Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy

OnkoFit II
Start date: August 1, 2020
Phase: N/A
Study type: Interventional

Evaluation of the impact of an activity tracker based fitness programme on the Qualitiy of Life after oncological therapy.

NCT ID: NCT04334239 Completed - Breast Cancer Clinical Trials

Effectiveness of Care in Certified Cancer Centres in Germany

WiZen
Start date: May 1, 2017
Phase:
Study type: Observational

Assessment of the effectiveness of care in certified cancer centres for eight cancer entities via a retrospective cohort study based on secondary data from statutory health insurance funds and population-based clinical cancer registries.

NCT ID: NCT04228237 Recruiting - Lung Cancer Clinical Trials

LUng CAncer focuS - Long-term Monitoring of Bronchogenic Carcinoma Patients (LUCAS)

LUCAS
Start date: June 1, 2018
Phase:
Study type: Observational

Long-term non-interventional monitoring of diagnostics and treatment patterns in newly diagnosed patients in selected pneumology centers in Czech republic.

NCT ID: NCT04222972 Active, not recruiting - Neoplasms Clinical Trials

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

AcceleRET-Lung
Start date: July 24, 2020
Phase: Phase 3
Study type: Interventional

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for participants with RET fusion-positive metastatic NSCLC who have not previously received systemic anticancer therapy for metastatic disease. Participants who have centrally confirmed progressive disease on the control arm have the option to crossover to pralsetinib.

NCT ID: NCT03786653 Completed - Bronchial Cancer Clinical Trials

Feasibility of Immunotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting (ImHADom)

ImHADom
Start date: March 6, 2019
Phase:
Study type: Observational

This observational prospective monosite study aims to describe, for the first time, management in a hospital-at-home programme of patients treated by immunotherapy for bronchial cancer. The feasibility in good conditions of this management, the patients' quality of life and their satisfaction will be evaluated.

NCT ID: NCT03684486 Completed - Clinical trials for Malignant Mesothelioma

Rehabilitation by Effort for Patients With Advanced Bronchial Cancer

RehabKBP
Start date: February 1, 2012
Phase: N/A
Study type: Interventional

Bronchopulmonary cancers or mesothelioma are associated with effort deconditioning due to pathology (chronic inflammation) and also to treatments (surgery, radiotherapy, chemotherapy); it's considerably alters patients quality of life. Investigators want to ensured the feasibility of rehabilitation by effort for these patients.